APA (7th ed.) Citation

V, S., L, J., E, B., A, C., H, T., P, B., & CE, K. (2025). Carrier screening for Alport syndrome: The clinical importance of heterozygosity for pathogenic or likely pathogenetic variants. Journal of genetic counseling, 34(3), e70045. https://doi.org/10.1002/jgc4.70045

Chicago Style (17th ed.) Citation

V, Souter, Johnson L, Becraft E, Cantu-Weinstein A, Tabriziani H, Benn P, and Kashtan CE. "Carrier Screening for Alport Syndrome: The Clinical Importance of Heterozygosity for Pathogenic or Likely Pathogenetic Variants." Journal of Genetic Counseling 34, no. 3 (2025): e70045. https://doi.org/10.1002/jgc4.70045.

MLA (9th ed.) Citation

V, Souter, et al. "Carrier Screening for Alport Syndrome: The Clinical Importance of Heterozygosity for Pathogenic or Likely Pathogenetic Variants." Journal of Genetic Counseling, vol. 34, no. 3, 2025, p. e70045, https://doi.org/10.1002/jgc4.70045.